Merck & Co., Inc. Restructuring and Related Cost, Number of Positions Eliminated
Merck & Co., Inc. (MRK) reported Restructuring and Related Cost, Number of Positions Eliminated of 2.16 thousand position for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2019-02-27
- Merck & Co., Inc. restructuring and related cost, number of positions eliminated for the quarter ending 2018-09-30 was 525.00 position, a 156.10% increase year-over-year.
- Merck & Co., Inc. restructuring and related cost, number of positions eliminated for the quarter ending 2018-06-30 was 635.00 position, a 33.68% increase year-over-year.
- Merck & Co., Inc. restructuring and related cost, number of positions eliminated for the quarter ending 2018-03-31 was 710.00 position, a 30.28% increase year-over-year.
- Merck & Co., Inc. restructuring and related cost, number of positions eliminated for the quarter ending 2017-09-30 was 205.00 position, a 31.67% decline year-over-year.
- Merck & Co., Inc. restructuring and related cost, number of positions eliminated for fiscal 2018 was 2.16K position, a 11.84% decline from fiscal 2017.
- Merck & Co., Inc. restructuring and related cost, number of positions eliminated for fiscal 2017 was 2.45K position, a 6.67% decline from fiscal 2016.
- Merck & Co., Inc. restructuring and related cost, number of positions eliminated for fiscal 2016 was 2.63K position, a 30.37% decline from fiscal 2015.
- Merck & Co., Inc. restructuring and related cost, number of positions eliminated for fiscal 2015 was 3.77K position, a 38.04% decline from fiscal 2014.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 3 month | Restructuring and Related Cost, Number of Positions Eliminated 6 month | Restructuring and Related Cost, Number of Positions Eliminated 9 month | Restructuring and Related Cost, Number of Positions Eliminated 12 month |
|---|---|---|---|---|
| 2018-12-31 | 2.16K position 10-K · filed 2019-02-27 | |||
| 2018-09-30 | 525.00 position 10-Q · filed 2018-11-06 | 1.87K position 10-Q · filed 2018-11-06 | ||
| 2018-06-30 | 635.00 position 10-Q · filed 2018-08-07 | 1.34K position 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | 710.00 position 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | 2.45K position 10-K · filed 2019-02-27 | |||
| 2017-09-30 | 205.00 position 10-Q · filed 2018-11-06 | 1.23K position 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | 475.00 position 10-Q · filed 2018-08-07 | 1.02K position 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | 545.00 position 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 2.63K position 10-K · filed 2019-02-27 | |||
| 2016-09-30 | 300.00 position 10-Q · filed 2017-11-07 | 1.35K position 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 585.00 position 10-Q · filed 2017-08-08 | 1.05K position 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | 470.00 position 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | 3.77K position 10-K · filed 2018-02-27 | |||
| 2015-09-30 | 685.00 position 10-Q · filed 2016-11-07 | 2.63K position 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | 860.00 position 10-Q · filed 2016-08-08 | 1.95K position 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | 1.08K position 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | 6.08K position 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |